Cargando…

Antibody-based strategies in HIV therapy

Antibody-based strategies have been introduced for a number of disease states, but represent a novel approach in the management of human immunodeficiency virus (HIV). Ibalizumab and leronlimab are monoclonal antibodies with unique mechanisms as a CD4-directed post-attachment inhibitor and a C-C chem...

Descripción completa

Detalles Bibliográficos
Autor principal: Kufel, Wesley D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd and International Society of Antimicrobial Chemotherapy. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546180/
https://www.ncbi.nlm.nih.gov/pubmed/33045349
http://dx.doi.org/10.1016/j.ijantimicag.2020.106186
_version_ 1783592177347067904
author Kufel, Wesley D.
author_facet Kufel, Wesley D.
author_sort Kufel, Wesley D.
collection PubMed
description Antibody-based strategies have been introduced for a number of disease states, but represent a novel approach in the management of human immunodeficiency virus (HIV). Ibalizumab and leronlimab are monoclonal antibodies with unique mechanisms as a CD4-directed post-attachment inhibitor and a C-C chemokine receptor type 5-directed inhibitor, respectively. These antibody-based strategies are generally well tolerated, have a favourable pharmacokinetic profile allowing for less-frequent dosing, and have a high barrier to resistance. Ibalizumab is currently approved by the US Food and Drug Administration (US FDA) for management of multi-drug-resistant (MDR) HIV infection in patients who are failing their current regimens. Clinical data demonstrated impressive antiretroviral activity with ibalizumab among a complex HIV population in combination with an optimized background regimen, where limited therapeutic options exist. To date, leronlimab has not been granted approval by the US FDA, but has been designated fast-track status. Leronlimab is being studied as a maintenance monotherapy agent in virologically suppressed patients, as well as for treatment of MDR HIV infection in patients who are failing their current regimens. Currently available data in both of these potential areas appear promising for leronlimab. The mechanism of action, pharmacokinetic profile, efficacy and safety of these novel antibody-based strategies represent an advance in the management of HIV. Future studies and post-marketing experience will further determine longer-term clinical efficacy, safety and resistance data for ibalizumab and leronlimab.
format Online
Article
Text
id pubmed-7546180
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier Ltd and International Society of Antimicrobial Chemotherapy.
record_format MEDLINE/PubMed
spelling pubmed-75461802020-10-13 Antibody-based strategies in HIV therapy Kufel, Wesley D. Int J Antimicrob Agents Article Antibody-based strategies have been introduced for a number of disease states, but represent a novel approach in the management of human immunodeficiency virus (HIV). Ibalizumab and leronlimab are monoclonal antibodies with unique mechanisms as a CD4-directed post-attachment inhibitor and a C-C chemokine receptor type 5-directed inhibitor, respectively. These antibody-based strategies are generally well tolerated, have a favourable pharmacokinetic profile allowing for less-frequent dosing, and have a high barrier to resistance. Ibalizumab is currently approved by the US Food and Drug Administration (US FDA) for management of multi-drug-resistant (MDR) HIV infection in patients who are failing their current regimens. Clinical data demonstrated impressive antiretroviral activity with ibalizumab among a complex HIV population in combination with an optimized background regimen, where limited therapeutic options exist. To date, leronlimab has not been granted approval by the US FDA, but has been designated fast-track status. Leronlimab is being studied as a maintenance monotherapy agent in virologically suppressed patients, as well as for treatment of MDR HIV infection in patients who are failing their current regimens. Currently available data in both of these potential areas appear promising for leronlimab. The mechanism of action, pharmacokinetic profile, efficacy and safety of these novel antibody-based strategies represent an advance in the management of HIV. Future studies and post-marketing experience will further determine longer-term clinical efficacy, safety and resistance data for ibalizumab and leronlimab. Elsevier Ltd and International Society of Antimicrobial Chemotherapy. 2020-12 2020-10-09 /pmc/articles/PMC7546180/ /pubmed/33045349 http://dx.doi.org/10.1016/j.ijantimicag.2020.106186 Text en © 2020 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Kufel, Wesley D.
Antibody-based strategies in HIV therapy
title Antibody-based strategies in HIV therapy
title_full Antibody-based strategies in HIV therapy
title_fullStr Antibody-based strategies in HIV therapy
title_full_unstemmed Antibody-based strategies in HIV therapy
title_short Antibody-based strategies in HIV therapy
title_sort antibody-based strategies in hiv therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546180/
https://www.ncbi.nlm.nih.gov/pubmed/33045349
http://dx.doi.org/10.1016/j.ijantimicag.2020.106186
work_keys_str_mv AT kufelwesleyd antibodybasedstrategiesinhivtherapy